Annika M. Astrand

BioPharmaceuticals R&D, AstraZeneca
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 33 publications

Discovery of a Selective Histone Deacetylase 6 Degrader (HDAC6 PROTAC) with a Short and Rigid Linker Demonstrating Sustained Knockdown of HDAC6 In Vivo.

Discovery of a Selective Histone Deacetylase 6 Degrader (HDAC6 PROTAC) with a Short and Rigid Linker Demonstrating Sustained Knockdown of HDAC6 In Vivo.

Journal: ACS medicinal chemistry letters

Published: February 11, 2026

Benralizumab in bronchiectasis: results from the phase 3 MAHALE study.

Benralizumab in bronchiectasis: results from the phase 3 MAHALE study.

Journal: ERJ open research

Published: November 05, 2025

A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma.

A plain language summary of the MIRACLE study: benralizumab in people in Asia with severe asthma.

Journal: Immunotherapy

Published: September 11, 2025

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.

Benralizumab efficacy and safety in severe asthma: A randomized trial in Asia.

Journal: Respiratory medicine

Published: January 12, 2024

Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective U.S. Insurance Claims Study.

Effect of COVID-19 on Bronchiectasis Exacerbation Rates: A Retrospective U.S. Insurance Claims Study.

Journal: Annals of the American Thoracic Society

Published: November 14, 2023

A comparative study of blood cell count in four automated hematology analyzers: An evaluation of the impact of preanalytical factors.

A comparative study of blood cell count in four automated hematology analyzers: An evaluation of the impact of preanalytical factors.

Journal: PloS one

Published: October 23, 2023

Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.

Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism.

Journal: Journal of medicinal chemistry

Published: October 05, 2023

Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.

Selective Janus kinase 1 inhibition resolves inflammation and restores hair growth offering a viable treatment option for alopecia areata.

Journal: Skin health and disease

Published: October 31, 2022

Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation.

Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation.

Journal: American journal of physiology. Lung cellular and molecular physiology

Published: September 13, 2022

HDAC6 inhibitor ACY-1083 shows lung epithelial protective features in COPD.

HDAC6 inhibitor ACY-1083 shows lung epithelial protective features in COPD.

Journal: PloS one

Published: March 17, 2022

Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota.

Stratification of alopecia areata reveals involvement of CD4 T cell populations and altered faecal microbiota.

Journal: Clinical and experimental immunology

Published: March 11, 2022

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis.

Journal: Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society

Published: November 19, 2021

Showing 1-12 of 33

Last Updated: 09/26/2026